Lv6
2790 积分 2022-09-02 加入
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
19天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
3个月前
已完结
First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
3个月前
已完结
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
4个月前
已关闭
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study
4个月前
已完结
P3.18.39 PRESERVE-003: A Phase 3 Study of Gotistobart Versus Docetaxel in Metastatic NSCLC After Progression on PD-(L)1 Inhibitors
5个月前
已关闭
Emerging Options and Future Strategies in Immunotherapy for Advanced Lung Squamous Cell Carcinoma
6个月前
已完结
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
7个月前
已完结
皖公网安备34019202002308
